Moffitt Cancer Center Receives Two NCI Grants to Further Prostate Cancer, Biomarker Research


Get Permission

Moffitt Cancer Center researchers recently received two National Cancer Institute (NCI) grants to further research in two areas
of study: bone metastasis in prostate cancer and imaging biomarkers for early cancers.

David ­Basanta, PhD

David ­Basanta, PhD

Conor Lynch, PhD

Conor Lynch, PhD

Moffitt Cancer Center researchers David ­Basanta, PhD, and Conor Lynch, PhD, have been awarded a $3.2 million U01 grant to investigate prostate cancer metastasis. Prostate cancer frequently spreads to the bone and can cause painful bony lesions and increased mortality for patients. Their study will integrate molecular, cellular, and clinical information into mathematical models to better understand key factors driving the disease to help target when metastasis may occur and identify new therapeutic targets for its prevention.

Early detection is one of the most effective strategies to save lives from most cancers. As part of a new $3.4 million U01 grant awarded to Jae K. Lee, PhD; Robert Gillies, PhD; John Heine, PhD; and Matthew Schabath, PhD, the Moffitt Imaging Biomarker Validation Center will be established to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. 

Moffitt will also become a Clinical Validation Center for the National Cancer Institute’s Early Detection Research Network. ■



Advertisement

Advertisement



Advertisement